The front page of the preprint article, showing title and authors

The abstract of the preprint

Forest plot showing primary and secondary trial outcomes, with non-inferiority margins

⚡️New preprint (not peer-reviewed)⚡️

In the SaDAPT trial with people with #HIV and #tuberculosis symptoms in 🇲🇼🇱🇸, we investigated if antiretroviral therapy should be initiated immediately, or delayed until TB results available. ssrn.com/abstract=523...

Outcomes (incl. IRIS) similar across both arms.

01.05.2025 07:10 — 👍 5    🔁 6    💬 1    📌 0

93% achieved HIV virological suppression by 32-weeks post
1HP, and there were no cases of cryptococcal relapse.

16.07.2025 13:24 — 👍 0    🔁 0    💬 0    📌 0

Day-14 dolutegravir C24h geometric mean (trough level)
was 0.61 (95%CI 0.32-1.16) mg/L, 9-fold higher than the
dolutegravir IC90 of 0.064 mg/L

16.07.2025 13:24 — 👍 0    🔁 0    💬 0    📌 0

Despite expected reductions in exposure, once-daily 50mg
dolutegravir and 800mg fluconazole dosing may be safe and
effective during 1HP amongst adults with advanced HIV
disease receiving treatment for cryptococcal meningitis.

16.07.2025 13:16 — 👍 0    🔁 0    💬 2    📌 0

Data from the intensive IMPROVE PK study amongst Ugandan adults with advanced HIV disease receiving once daily DTG with 1HP presented at IAS this week.

16.07.2025 13:15 — 👍 0    🔁 0    💬 1    📌 0

Can't believe the EMPIRICAL study showing reduced MORTALITY in kids with pneumonia given valganciclovir didn't get an oral! Come on #IAS2025. This is a VERY important finding.

16.07.2025 08:21 — 👍 1    🔁 2    💬 1    📌 0

Cumulative 6-month mortality amongst 146 adults with advanced HIV disease, stratified by baseline CMV viraemia status

Jayne Ellis presenting data from our cohort with CD4 <100 undergoing CrAg screening in SA at #IAS2025 (poster 2803)

59% (86/146) had CMV viraemia - strongly & independently associated with ⬆️mortality, more than quadrupling odds of death at 6-months (adjusted OR 4.02, 95%CI 1.27-12.7)

14.07.2025 08:36 — 👍 2    🔁 1    💬 0    📌 1